Clinical Trial Update: UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase II trial evaluating tailored-dose docetaxel in combination with trastuzumab for HER2-positive metastatic breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: HER-2 Positive Metastatic Breast Cancer | Phase 2 | Status: COMPLETED